Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma

Patients with mRCC who progress on 50 mg sunitinib dose, may derive a clinical benefit and prolonged survival from dose-escalation with acceptable toxicity profiles. These results need to be confirmed in prospective studies with the aim to overcome drug resistance and delay the change in systemic therapy at progression.